GlassScriptPhysician profile
Emma Weber
NPI 1962058370
$7,858.60
in general payments reported to CMS, 2019-2025
25 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,662 · 2022: $2,256 · 2023: $1,359 · 2024: $1,401 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,865 · Education: $75.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,865.09 |
| Education | $75.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,905.32 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $644.98 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $613.92 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $600.10 | 2021-2025 | |
| Genzyme Corporation | $557.92 | 2021-2025 | |
| Lilly USA, LLC | $478.15 | 2021-2025 | Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $460.82 | 2021-2025 | Winlevi |
| Pfizer INC. | $402.24 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $390.86 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $224.72 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $206.47 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Ucb, INC. | $205.78 | 2021-2025 | Bimzelx |
| Amgen INC. | $195.36 | 2023-2024 | Otezla, Enbrel |
| Janssen Scientific Affairs, LLC | $147.09 | 2022 | |
| Vyne Pharmaceuticals INC. | $133.69 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.35 | 2022-2024 | Spevigo |
| Incyte Corporation | $120.76 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $107.27 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $89.18 | 2023-2024 | Ycanth |
| Genentech USA, INC. | $58.15 | 2021 | |
| Organon LLC | $57.06 | 2023-2025 | Hadlima, Vtama |
| Almirall LLC | $42.63 | 2021-2022 | |
| Journey Medical Corporation | $35.67 | 2025 | |
| Dermavant Sciences, INC. | $29.95 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.16 | 2025 | Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.